Testicular cancer case study
Testicular cancer case study
There are many cases of cancer has been detected as in which most common type are: Breast cancer, prostate cancer, testicular cancer and skin cancer. In cancer it is not that it is caused by only a single factor. There are many factors which are responsible for that such as external factors (smoking, radiation and infectious organisms) and may also by internal factors (inherited genes, immune conditions).
Many people are controlling these external ones like smoking etc. to combat the disease mainly of which is testicular one.
Many researchers have found that in and European countries the controlling of external factor can combat testicular cancer.
In as study by a group of scientists, in Norway Mr. Tom Grotmol of the Cancer Registry and his colleagues examined 3,000 birth records from 1951 to 1971 and comparing with them the data indicating the number of man who are born in Norway and between 1951-1971 and many of them who are born after that.
New Study Indicates Smallpox Vaccination Effective For Decades
Although naturally occurring smallpox was eradicated in 1977, there is concern that bioterrorists might obtain smallpox from a laboratory and release it into the population. Under such circumstances, the supply of smallpox vaccine may be insufficient for universal administration.
The Government Of Canada Procures IMVAMUNE(R) Smallpox Vaccine For The Country's Biological Preparedness
Following a Request for Proposal issued in 2007 with the intent to procure an MVA-based, third generation smallpox vaccine, Public Works and Government Services Canada, on behalf of the Canadian Department of National Defence, has awarded a contract to Bavarian Nordic for the delivery of IMVAMUNE®. The Canadian authorities intend to use IMVAMUNE® as part of the country's bio-preparedness programme.
PS-Targeting Antibodies May Represent A New Class Of Drugs With Broad Potential To Treat Viral Infections
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) has reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models.
